S&P 500   3,319.18 (+1.16%)
DOW   27,323.41 (+0.65%)
QQQ   272.11 (+1.72%)
AAPL   111.56 (+1.34%)
MSFT   207.05 (+2.23%)
FB   254.53 (+2.57%)
GOOGL   1,458.41 (+1.98%)
AMZN   3,114.23 (+5.19%)
NVDA   502.89 (+0.44%)
TSLA   423.25 (-5.82%)
BABA   274.37 (+0.20%)
CGC   16.08 (+2.16%)
GE   6.25 (-1.57%)
MU   49.58 (+0.87%)
AMD   77.33 (-0.78%)
T   28.52 (-0.38%)
F   6.80 (-1.02%)
ACB   7.46 (+18.04%)
GILD   63.53 (-1.06%)
NFLX   490.48 (+0.64%)
DIS   127.14 (+1.38%)
BAC   23.86 (-2.49%)
BA   156.63 (+0.18%)
S&P 500   3,319.18 (+1.16%)
DOW   27,323.41 (+0.65%)
QQQ   272.11 (+1.72%)
AAPL   111.56 (+1.34%)
MSFT   207.05 (+2.23%)
FB   254.53 (+2.57%)
GOOGL   1,458.41 (+1.98%)
AMZN   3,114.23 (+5.19%)
NVDA   502.89 (+0.44%)
TSLA   423.25 (-5.82%)
BABA   274.37 (+0.20%)
CGC   16.08 (+2.16%)
GE   6.25 (-1.57%)
MU   49.58 (+0.87%)
AMD   77.33 (-0.78%)
T   28.52 (-0.38%)
F   6.80 (-1.02%)
ACB   7.46 (+18.04%)
GILD   63.53 (-1.06%)
NFLX   490.48 (+0.64%)
DIS   127.14 (+1.38%)
BAC   23.86 (-2.49%)
BA   156.63 (+0.18%)
S&P 500   3,319.18 (+1.16%)
DOW   27,323.41 (+0.65%)
QQQ   272.11 (+1.72%)
AAPL   111.56 (+1.34%)
MSFT   207.05 (+2.23%)
FB   254.53 (+2.57%)
GOOGL   1,458.41 (+1.98%)
AMZN   3,114.23 (+5.19%)
NVDA   502.89 (+0.44%)
TSLA   423.25 (-5.82%)
BABA   274.37 (+0.20%)
CGC   16.08 (+2.16%)
GE   6.25 (-1.57%)
MU   49.58 (+0.87%)
AMD   77.33 (-0.78%)
T   28.52 (-0.38%)
F   6.80 (-1.02%)
ACB   7.46 (+18.04%)
GILD   63.53 (-1.06%)
NFLX   490.48 (+0.64%)
DIS   127.14 (+1.38%)
BAC   23.86 (-2.49%)
BA   156.63 (+0.18%)
S&P 500   3,319.18 (+1.16%)
DOW   27,323.41 (+0.65%)
QQQ   272.11 (+1.72%)
AAPL   111.56 (+1.34%)
MSFT   207.05 (+2.23%)
FB   254.53 (+2.57%)
GOOGL   1,458.41 (+1.98%)
AMZN   3,114.23 (+5.19%)
NVDA   502.89 (+0.44%)
TSLA   423.25 (-5.82%)
BABA   274.37 (+0.20%)
CGC   16.08 (+2.16%)
GE   6.25 (-1.57%)
MU   49.58 (+0.87%)
AMD   77.33 (-0.78%)
T   28.52 (-0.38%)
F   6.80 (-1.02%)
ACB   7.46 (+18.04%)
GILD   63.53 (-1.06%)
NFLX   490.48 (+0.64%)
DIS   127.14 (+1.38%)
BAC   23.86 (-2.49%)
BA   156.63 (+0.18%)
Log in
NASDAQ:GOSS

Gossamer Bio Stock Forecast, Price & News

$12.42
-0.08 (-0.64 %)
(As of 09/22/2020 03:25 PM ET)
Add
Compare
Today's Range
$12.27
Now: $12.42
$12.52
50-Day Range
$11.92
MA: $13.37
$14.29
52-Week Range
$7.52
Now: $12.42
$27.15
Volume9,818 shs
Average Volume529,679 shs
Market Capitalization$941.78 million
P/E RatioN/A
Dividend YieldN/A
Beta1.17
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist of prostaglandin D2 receptor 2 that is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma, as well as that has completed Phase I clinical trial for chronic rhinosinusitis with nasal polyps, without nasal polyps, and chronic spontaneous urticarial; GB002, a platelet-derived growth factor, receptor kinase inhibitor that is in Phase I clinical trial for the treatment of pulmonary arterial hypertension; GB004, an oral small molecule that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and GB1275, an oral small molecule for the treatment of oncology indications. It has license agreement with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was founded in 2015 and is headquartered in San Diego, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.11 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GOSS
CUSIPN/A
CIKN/A
Phone858-922-0718

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$5.34 per share

Profitability

Net Income$-180,310,000.00

Miscellaneous

Employees118
Market Cap$941.78 million
Next Earnings Date11/10/2020 (Estimated)
OptionableNot Optionable
$12.42
-0.08 (-0.64 %)
(As of 09/22/2020 03:25 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive GOSS News and Ratings via Email

Sign-up to receive the latest news and ratings for GOSS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Gossamer Bio (NASDAQ:GOSS) Frequently Asked Questions

How has Gossamer Bio's stock price been impacted by COVID-19?

Gossamer Bio's stock was trading at $10.59 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, GOSS shares have increased by 17.3% and is now trading at $12.42.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Gossamer Bio?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gossamer Bio in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Gossamer Bio
.

When is Gossamer Bio's next earnings date?

Gossamer Bio is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Gossamer Bio
.

How were Gossamer Bio's earnings last quarter?

Gossamer Bio Inc (NASDAQ:GOSS) announced its quarterly earnings data on Tuesday, August, 11th. The company reported ($1.00) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.86) by $0.14.
View Gossamer Bio's earnings history
.

What price target have analysts set for GOSS?

7 brokerages have issued 1 year price objectives for Gossamer Bio's shares. Their forecasts range from $21.00 to $36.00. On average, they expect Gossamer Bio's stock price to reach $30.57 in the next twelve months. This suggests a possible upside of 146.1% from the stock's current price.
View analysts' price targets for Gossamer Bio
.

Who are some of Gossamer Bio's key competitors?

What other stocks do shareholders of Gossamer Bio own?

Who are Gossamer Bio's key executives?

Gossamer Bio's management team includes the following people:
  • Mr. Faheem Hasnain, Co-Founder & Exec. Chairman (Age 61)
  • Dr. Sheila K. Gujrathi M.D., Co-Founder, Pres, CEO & Director (Age 49)
  • Mr. Bryan Giraudo, Chief Financial Officer (Age 43)
  • Mr. Christian Waage, Exec. VP, Gen. Counsel & Sec. (Age 52)
  • Dr. Jakob Dupont, Chief Medical Officer (Age 54)

When did Gossamer Bio IPO?

(GOSS) raised $230 million in an initial public offering on Friday, February 8th 2019. The company issued 14,400,000 shares at $16.00 per share. BofA Merrill Lynch, Leerink Partners, Barclays and Evercore ISI served as the underwriters for the IPO.

What is Gossamer Bio's stock symbol?

Gossamer Bio trades on the NASDAQ under the ticker symbol "GOSS."

Who are Gossamer Bio's major shareholders?

Gossamer Bio's stock is owned by a variety of retail and institutional investors. Top institutional investors include Hillhouse Capital Advisors LTD. (11.18%), Vanguard Group Inc. (7.36%), Omega Fund Management LLC (4.38%), Artal Group S.A. (4.01%), Federated Hermes Inc. (2.86%) and Alyeska Investment Group L.P. (2.25%). Company insiders that own Gossamer Bio stock include Bryan Giraudo, Faheem Hasnain, Fund V Gp LP Omega, Jakob Dupont, Luisa Salter-Cid, Russell J Cox and Waage Christian.
View institutional ownership trends for Gossamer Bio
.

Which institutional investors are selling Gossamer Bio stock?

GOSS stock was sold by a variety of institutional investors in the last quarter, including Omega Fund Management LLC, FMR LLC, FMR LLC, Alps Advisors Inc., Ensign Peak Advisors Inc, and Nuveen Asset Management LLC.
View insider buying and selling activity for Gossamer Bio
.

Which institutional investors are buying Gossamer Bio stock?

GOSS stock was acquired by a variety of institutional investors in the last quarter, including Hillhouse Capital Advisors LTD., Vanguard Group Inc., Alyeska Investment Group L.P., Artal Group S.A., Jennison Associates LLC, Ikarian Capital LLC, Federated Hermes Inc., and Hudson Bay Capital Management LP. Company insiders that have bought Gossamer Bio stock in the last two years include Bryan Giraudo, Faheem Hasnain, Russell J Cox, and Waage Christian.
View insider buying and selling activity for Gossamer Bio
.

How do I buy shares of Gossamer Bio?

Shares of GOSS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Gossamer Bio's stock price today?

One share of GOSS stock can currently be purchased for approximately $12.42.

How big of a company is Gossamer Bio?

Gossamer Bio has a market capitalization of $941.78 million. The company earns $-180,310,000.00 in net income (profit) each year or ($3.29) on an earnings per share basis. Gossamer Bio employs 118 workers across the globe.

What is Gossamer Bio's official website?

The official website for Gossamer Bio is www.gossamerbio.com.

How can I contact Gossamer Bio?

Gossamer Bio's mailing address is 3013 SCIENCE PARK, SAN DIEGO CA, 92121. The company can be reached via phone at 858-922-0718.

This page was last updated on 9/22/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.